Puma Biotechnology Inc PBYI Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$8.25 down $1.52, 15.56% at close Nov 6
Last close · Previous close $9.77
- Market cap
- $419.92MAt the Nov 6 close
- P/E ratio
- 15.87On last 12 months’ EPS
- Diluted EPS
- $0.52Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$8.25down $1.52, 15.56%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$9.77Nov 5
- Volume1.28MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume418.11KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $4.58 to $11.50; now $8.25
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
PBYI beat the S&P 500 in 5 of 7 periods.
| Period | PBYI and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PBYI: down 13.2% S&P 500: down 5.6% | PBYI trailed the S&P 500 by 7.6 percentage points Trailed |
| 3M | PBYI: up 1.6% S&P 500: down 4.1% | PBYI beat the S&P 500 by 5.7 percentage points Beat |
| YTD | PBYI: up 38.7% S&P 500: up 8.7% | PBYI beat the S&P 500 by 30.0 percentage points Beat |
| 1Y | PBYI: up 68.4% S&P 500: up 10.9% | PBYI beat the S&P 500 by 57.5 percentage points Beat |
| Long term | ||
| 3Y | PBYI: up 193.6% S&P 500: up 75.0% +43.2% vs +20.5% a year | PBYI beat the S&P 500 by 118.6 percentage points Beat |
| 5Y | PBYI: up 105.7% S&P 500: up 67.8% +15.5% vs +10.9% a year | PBYI beat the S&P 500 by 37.9 percentage points Beat |
| 10Y | PBYI: down 77.2% S&P 500: up 313.1% −13.7% vs +15.2% a year | PBYI trailed the S&P 500 by 390.3 percentage points Trailed |
$10,000 invested in PBYI 10 years ago (Nov 4, 2016) would be worth about $2,279 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
PBYI beat the S&P 500 in 5 of 7 periods.
| Period | PBYI and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PBYI: down 13.2% S&P 500: down 5.6% | PBYI trailed the S&P 500 by 7.6 percentage points Trailed |
| 3M | PBYI: up 1.6% S&P 500: down 4.3% | PBYI beat the S&P 500 by 5.9 percentage points Beat |
| YTD | PBYI: up 38.7% S&P 500: up 7.8% | PBYI beat the S&P 500 by 30.9 percentage points Beat |
| 1Y | PBYI: up 68.4% S&P 500: up 9.7% | PBYI beat the S&P 500 by 58.7 percentage points Beat |
| Long term | ||
| 3Y | PBYI: up 193.6% S&P 500: up 68.8% +43.2% vs +19.1% a year | PBYI beat the S&P 500 by 124.8 percentage points Beat |
| 5Y | PBYI: up 105.7% S&P 500: up 56.9% +15.5% vs +9.4% a year | PBYI beat the S&P 500 by 48.8 percentage points Beat |
| 10Y | PBYI: down 77.2% S&P 500: up 252.6% −13.7% vs +13.4% a year | PBYI trailed the S&P 500 by 329.8 percentage points Trailed |
$10,000 invested in PBYI 10 years ago (Nov 4, 2016) would be worth about $2,279 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$275.07
Closing high on . Now 97.0% below that record.
Split-adjusted daily closes since Apr 24, 2012.
Stock splits
PBYI hasn’t split since its price history begins in 2012.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
15.9×The Nov 6 close ÷ diluted EPS over the last 12 months ($0.52)
The range covers daily P/E ratios from Oct 28, 2021 to Nov 6, 2026, each based on the previous 12 months of earnings.
PBYI trades at 15.9× its earnings over the last 12 months, above its 5-year median of 11.9×. In plain terms, buyers are paying about $16 for each $1 of profit from the past year. How to read P/E
Other valuation measures
- 1.8×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 3.0×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - 7.3×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - 9.80%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $330.83MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own PBYI DCF in Excel. Value Puma Biotechnology with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $231.24Mdown 2.9%
- Net income
- $26.72Mdown 44.9%
- Diluted EPS
- $0.52down 47.5%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $80.54M | $20.32M | $0.41 |
| Q4 FY24 (Dec 31, 2024) | $59.08M | $19.31M | $0.40 |
| Q1 FY25 (Mar 31, 2025) | $46.01M | $2.97M | $0.06 |
| Q2 FY25 (Jun 30, 2025) | $52.44M | $5.86M | $0.12 |
| Q3 FY25 (Sep 30, 2025) | $54.48M | $8.84M | $0.17 |
| Q4 FY25 (Dec 31, 2025) | $75.45M | $13.44M | $0.26 |
| Q1 FY26 (Mar 31, 2026) | $44.81M | −$3.75M | −$0.07 |
| Q2 FY26 (Jun 30, 2026) | $56.50M | $8.19M | $0.16 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $253.16M | −$29.13M | −$0.72 |
| FY22 (Dec 31, 2022) | $228.03M | $2.00K | $0.00 |
| FY23 (Dec 31, 2023) | $235.64M | $21.59M | $0.45 |
| FY24 (Dec 31, 2024) | $230.47M | $30.28M | $0.62 |
| FY25 (Dec 31, 2025) | $228.37M | $31.11M | $0.61 |
Margins
- Gross 74.8%
- Operating 13.2%
- Net 11.6%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $41.16MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$41.15MLast 12 months
- Capital spending$10.00KLast 12 months
- 17.8%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $0.00Last 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
0% of free cash flow
Balance sheet
- $93.90MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$4.82MAs of Jun 30, 2026
- Net cash$89.09MAs of Jun 30, 2026
- 2.91As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.03As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 7 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 20.9%Last 12 months
Over the last 12 months, Puma Biotechnology’s net income was 20.9% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 13.3%Last 12 months
Over the last 12 months, Puma Biotechnology’s net income was 13.3% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Puma Biotechnology Inc
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc. In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
PBYI news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
PBYI stock FAQ
What is PBYI stock’s price today?
Puma Biotechnology (PBYI) traded at $8.25 at the close on , down $1.52 (15.56%) from the previous close of $9.77. Over the past 52 weeks it has traded between $4.58 and $11.50.
If you invested $1,000 in PBYI 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in PBYI on would be worth about $228 at the close on , a total return of −77.2%. The same $1,000 would be worth $2,057 if invested five years ago and $1,684 if invested one year ago. Past performance doesn’t predict future returns.
What is Puma Biotechnology’s market cap?
Puma Biotechnology’s market capitalization is about $419.9 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $8.25 (how market cap works). Puma Biotechnology reported 50.90M shares outstanding at the end of its latest quarter ().
What is PBYI’s P/E ratio?
PBYI trades at 15.9 times its diluted earnings over the four quarters to ($0.52 per share), at the close. Over the past five years its P/E has ranged from 3.1 to 57.4, with a median of 11.9. (How the P/E ratio works.)
How much revenue does Puma Biotechnology make?
Puma Biotechnology reported $231.2 million of revenue over the four quarters to , down 2.9% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $56.5 million, up 7.8% from a year earlier.
Is Puma Biotechnology profitable?
Yes. Puma Biotechnology earned $26.7 million of net income over the four quarters to , a net margin of 11.6%, and its operating margin was 13.2% (what margins tell you).
What are PBYI’s earnings per share?
PBYI’s diluted earnings per share were $0.52 over the four quarters to , compared with $0.99 in the twelve months before. The latest quarter (Q2 FY26) brought $0.16 per share, against $0.12 a year earlier (how EPS works).
Does PBYI pay a dividend?
Puma Biotechnology hasn’t paid a dividend in the last twelve months.
What is PBYI’s 52-week high and low?
Over the past 52 weeks PBYI has traded as low as $4.58 and as high as $11.50. At $8.25 at the close on , it is 28.3% below that high and 80.3% above the low.
What is PBYI’s all-time high?
PBYI’s highest closing price was $275.07 on , adjusted for stock splits. At $8.25 at the close on , it is 97.0% below that record.
Has PBYI stock ever split?
No. PBYI hasn’t split since its price history begins in 2012.
How has PBYI stock performed?
Including dividends and measured to the close on , PBYI has returned +38.7% so far this year and +68.4% over the past year, and +105.7% over five years (+15.5% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Puma Biotechnology in?
Puma Biotechnology is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does PBYI trade on?
Puma Biotechnology trades on the Nasdaq under the ticker symbol PBYI. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.